|Bid||68.00 x 0|
|Ask||68.50 x 0|
|Day's Range||67.00 - 67.00|
|52 Week Range||55.40 - 69.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for ZEGA.MULearn more
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years. With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS). As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.
In this article, we discuss 12 best growth stocks to buy and hold in 2023 according to billionaire Rajiv Jain. If you want to see more stocks in this selection, check out 5 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain. Bloomberg reported on May 23 that Rajiv Jain, […]
WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance
WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023.
Innoviva Inc's (NASDAQ: INVA) affiliate Entasis Therapeutics Inc received FDA approval for Xacduro (sulbactam and durlobactam for injection), co-packaged as a treatment for hospital-acquired pneumonia. The approval covers patients 18 years and older for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex. Innoviva acquired Entasis Therapeutics in May 2022 for $2.20 per sha
WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o
AstraZeneca has big business in China. The British pharmaceutical company is the biggest drugmaker in the country, where it makes 13% of its revenue.
Bloomberg Alibaba's Cloud Business Spinoff - What's Going On With Alibaba Stock Friday Alibaba Group Holding Limited's (NYSE: BABA) move to fully spin out a potentially transformative $12 billion cloud business has fueled speculation of it succumbing to market or political realities. Analysts value the cloud business at upwards of $30 billion, a prime beneficiary of a post-ChatGPT frenzy mirroring the success of Amazon.Com Inc's (NASDAQ: AMZN) cloud unit Amazon Web Services. Alibaba splurged ten
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To
During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China that "loves the Communist Party." Wang, who also holds the position of global executive vice president, commented at the event, Reuters reported citing a person familiar with the matter and photos shared. Also Read: One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps. A
Global drugmaker AstraZeneca will seek to be a patriotic company in China that "loves the Communist Party", its China president said at an event on Friday. Wang Lei, who is also the company's global executive vice president, made the comments at an event in the eastern city of Wuxi which the firm organised to celebrate its 30th year in China, according to a person familiar with the matter and photos shared with Reuters. While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies.
In the last decade, few companies have touched the magic trillion-dollar valuation. Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), and Alphabet (NASDAQ:GOOG, NASDAQ: GOOGL) are the names worth mentioning. While these businesses will continue to create value, I am more interested in finding the next trillion-dollar companies. An interesting point to note is that most of the trillion-dollar valuation companies in the last decade were from the technology sector. Of course, there are potential opportuni
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […]
AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) in combination with chemotherapy for locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The results showed that Tagrisso plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Tagrisso alone. Related: Ast
WILMINGTON, Del., May 17, 2023--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday. The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso. The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said. AstraZeneca decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the British drugmaker said in an emailed statement. PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.
LONDON (Reuters) -AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said. AstraZeneca decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the British drugmaker said in an emailed statement. PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.
AstraZeneca's (LON:AZN) stock is up by 4.2% over the past three months. However, the company's financials look a bit...
Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios. British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.
In this article, we will take a look at the 25 best US cities for people with allergies. If you want to see more cities in this selection, go to the 5 Best US Cities for People With Allergies. According to Allied Market Research, the market for allergy treatments was valued at $24.6 billion in […]
Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. But Sanofi stock dipped Friday.
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have revealed data from a real-world trial of their candidate nirsevimab, a long-acting antibody. In November, nirsevimab was approved in Europe, dubbed Beyfortus, to prevent RSV-LRTD in newborns and infants during their first RSV season. The phase 3 HARMONIE study recruited over 8,000 infants 12 months and younger. Infants who received a single dose of the a